We find that knockdown of ARNT in cultured Min6 ual variability in PDX-1 and glucokinase. mRNAs for the glucose transporters GLUT1, GLUT2, cells using small interfering RNA (siRNA) and β cellspecific knockout of ARNT in mice produces both deand GLUT3 ( Figure 2B ), as well as GLUT9 and GLUT10 (data not shown), were all clearly detectable in islets, fects in glucose-stimulated insulin release and alterations in islet gene expression that mimic those in islets but there were no significant differences in expression. Interestingly, in human islets, GLUT1 was much more of humans with type 2 diabetes. Together, these different models suggest an important role for ARNT and highly expressed than GLUT2. By RT-PCR, GLUT1 expression in controls was 4.4 times that of GLUT2 (p = altered gene expression in impaired β cell function and the pathogenesis of human type 2 diabetes. 0.037). Markedly higher expression of GLUT1 compared to GLUT2 in human islets has been previously reported (De Vos et al., 1995) and is a potentially imporResults tant difference between human and rodent islets. In contrast to glucose-transporter expression, sevMicroarray Analysis eral downstream enzymes in the glycolytic pathway cRNA prepared from islets of seven normal and five were significantly decreased in diabetic islets, including type 2 diabetic patients was hybridized to Affymetrix glucose-6-phosphate isomerase (G6PI), aldolase (Aldo), U133A and B microarrays. Demographic characterisphosphofructokinase (PFK), and phosphoglucomutase tics are shown in Table S1 in the Supplemental Data (PGM) at 16%, 18%, 19%, and 11% of control (p = available with this article online. Of the w44,928 genes 0.002, p < 0.0001, p < 0.0001, and p < 0.0001, respecand ESTs represented on these chips, 370 showed diftively). ferences in expression at the p < 0.01 level (Table S2) .
Among the insulin-signaling genes, insulin-receptor Of these, 243 were upregulated in diabetic subjects relmRNA was significantly lower in subjects with diabetes ative to normal, and 137 were downregulated. All of the (23% of control, p = 0.027) ( Figure 2C ). In addition, IRS2 microarray data will be available on the website of the and Akt2 mRNAs were significantly and markedly lower Diabetes Genome Anatomy Project (DGAP) at http:// in the diabetic subjects (9%, p < 0.0001, and 16% of www.diabetesgenome.org. control, p = 0.008, respectively). On the other hand, None of the 13 genes that were recently reported expression of SHIP2, a phosphatidylinositol phosphato best differentiate acinar and islet contributions to tase that inhibits insulin signaling, was significantly inmRNA (Cras-Meneur et al., 2004) differed, indicating creased in islets of the type 2 diabetics (81% increase, equivalent islet purification in the two groups (Figure p = 0.04). These changes would be likely to lead to im-1A). As expected, expression of insulin, glucagon, sopaired insulin signaling in diabetic islets. There were no matostatin, and pancreatic polypeptide mRNAs in husignificant differences in expression of proinsulin, IRS4, man islets was high but did not differ significantly phosphatidylinositol (PI) 3-kinase subunits, or Akt1 bebetween groups ( Figure 1B) . Figure 1C shows array extween the two groups (data not shown). pression of a number of non-MODY transcription facIn mice, the two alternately spliced isoforms of the tors known to be associated with β cell development insulin receptor have been suggested to play different and function. None of these was significantly altered, roles in regulation of islet gene expression (Leibiger et although Foxa2/HNF3β and Pax4 both showed trends al., 2001). Furthermore, some studies have suggested to increased expression in diabetics (p = 0.06). Expresan altered ratio of expression of insulin-receptor isosion of neurogenin3 was low and did not differ beforms in muscle of humans with type 2 diabetes (Nortween groups. gren et al., 1993). Semiquantitative PCR using primers MAPPFinder 2.0 analysis of the microarray data idenselected to amplify both A (minus exon 11) and B (plus tified the group of RNA-processing genes as signifiexon 11) isoforms (Entingh et al., 2003) revealed that cantly altered ( Figure S1 ). No other group of genes was isoform A was the dominantly expressed form in human identified using this approach. Therefore, we focused islets and confirmed the decrease in total insulin-recepour initial attention on families of genes that have pretor mRNA, but the ratio of isoforms did not differ signifiviously been linked to β cell function.
cantly between the diabetics and controls (data not shown). Expression of MODY, Glucose-Sensing, and InsulinSignaling Genes Was Altered in Human Islets Three groups of genes that have been shown to affect ARNT Expression Was Decreased in Islets from Humans with Type 2 Diabetes Mellitus glucose-stimulated insulin secretion are the MODY genes, glucose-uptake and -metabolism genes, and sevBy microarray, the most significantly decreased gene in islets from people with type 2 diabetes was ARNT, 18% eral insulin-signaling genes. Expression of genes from these groups was measured by both microarray and of control levels, p = 0.000012, Figure 2D . Real-time PCR confirmed a substantial and highly statistically sigquantitative real-time PCR. For simplicity, the quantitative RT-PCR data are presented here, but as noted above, nificant decrease in ARNT, with expression at 10.2% of normal islets, p < 0.0000001, Figure 2E . Among the the array data are available at the DGAP website. bHLH-PAS family members, AhR, BMAL1, HIF1α, and duced marked reductions in glucose-stimulated insulin HIF2α/EPAS1 were detected in human islets by microsecretion from Min6 cells. Group 2 produced a dearray and real-time PCR. Of these, AhR, BMAL1, and crease of approximately 50% in the stimulatable com-HIF1α were also significantly decreased ( Figure 2F) . ponent of insulin release (p < 0.01 by ANOVA for repeated measures), whereas group 3 abolished glucose-stimulated insulin release (p < 0.001 by ANOVA) Small Interfering RNA Impaired Glucose-Stimulated ( Figure 3B ).
Insulin Release and mRNA Expression in Min6 Cells
Real-time PCR of RNA isolated from Min6 cells reTo determine the role of ARNT in a glucose-responsive vealed that siRNA treatment also led to significant de-β cell-derived model, Min6 cells were treated with creases in the expression of HNF4α (60% decrease, p = siRNA directed against ARNT or scrambled-siRNA con-0.012) and HNF1α (68% decrease, p < 0.0001) (Figure trol. As shown in Figure 3A , siRNA treatments de-3C); G6PI (35% decrease, p = 0.039), aldolase (50% decreased ARNT protein with varying effectiveness. This crease, p = 0.048), and PFK (59% decrease, p = 0.047) was paralleled by decreases in ARNT mRNA (data not ( Figure 3D) ; and insulin receptor (88% decrease, p = shown). Scrambled siRNA (control, group 1) had no ef-0.044), IRS2 (78% decrease, p < 0.001), and Akt2 (97% fect on ARNT protein levels. Among the six active decrease, p < 0.0001) ( Figure 3E ). Together, these marked siRNAs tested, there were two levels of effect: an interchanges in gene expression would be expected to impair mediately effective group (group 2), which caused a β cell function, glucose metabolism, and glucose-responmoderate decrease in ARNT (approximately 40%) and sive insulin secretion, which was seen in Figure 3B . the most effective siRNAs, which markedly reduced
The changes in mRNA expression in the Min6 cells ARNT (>80% decrease, group 3). When each of these with reduced ARNT expression closely paralleled the was assessed for effect on β cell function, both the moderately effective and most effective siRNAs prochanges observed in the human islets from people with hibit a 40% reduction in peak levels of insulin following (3 or 5 mM). However, at glucose concentrations of 8.3 and 11 mM, insulin release from female β-ARNT islets combined arginine and glucose stimulation compared was significantly lower than in controls (p < 0.01 and p < to controls (p < 0.05, Figure 4G) . 0.05, respectively) ( Figure 5D ). This trend continued at 25 mM glucose, but the difference did not achieve staIslets from ␤-ARNT Knockout Mice Display Defective tistical significance at this high glucose level. In male Glucose-Stimulated Insulin Release and Altered β-ARNT mice, insulin release was also lower at both 11 mRNA Expression and 25 mM glucose ( Figure 5E ). To determine the basis of the defect in glucose-stim-RNA was isolated from the remaining islets and anaulated insulin secretion in the β-ARNT mice, islets from lyzed by real-time PCR. The results for male and female β-ARNT and control animals were examined. Isolated mice did not differ significantly, so they are presented islets were stained with a cocktail for insulin, DAPI, and together. As shown in Figure 6A , of the genes associ-ARNT. As shown, ARNT deletion was highly effective in ated with MODY in humans, HNF4α was substantially the knockout mice ( Figure 5A ). β cell mass was examand significantly decreased (92% decrease, p < 0.0001). ined by an observer blinded to mouse genotype and Expression of glucose transporters GLUT1 and GLUT2 did not differ between β-ARNT and control mice (Figure was not altered. However, G6PI and aldolase were sig-5B). Islet isolation gave similar yields of 227 ± 19 and nificantly decreased (46%, p = 0.044 and 54%, p = 236 ± 12 islets in β-ARNT and control mice, respectively. 0.048, respectively) ( Figure 6B ). Insulin-receptor exTotal insulin content did not differ between β-ARNT and pression was decreased by 46% (p < 0.0001), and there control mice for either female or male mice ( Figure 5C) . was a 73% decrease in Akt2 expression (p = 0.007) (FigUsing islets from either females or males, insulin reure 6C) . Again, the changes observed in mRNA expression in β-ARNT islets paralleled those seen in human lease was low and equal at low glucose concentrations There was a trend toward decreased ARNT expreschange in βARNT mouse islets is shown in Figure 6D for genes with a putative ARNT binding site in the first sion in βIRKO mice (74% of expression in IR-lox animals, p = 0.07) and no significant change in ARNT ex-2 kb of their promoter regions and was significant (r 2 = 0.36, p = 0.038). Interestingly, for the mRNAs examined, pression in db/db or ob/ob mice (Figure 7) . These results suggest that the substantial decrease in ARNT the results for male and female mice did not differ significantly, suggesting that the ability of male mice to in human islets is not likely to be mediated solely by diabetes, hyperglycemia, or insulin resistance. maintain near-normal glucose tolerance and insulin secretion depends on compensation by some other component of the insulin-secretion or insulin-action Discussion pathway.
Among potential ARNT partners, expression of mRNAs It is well known that humans with type 2 diabetes exfor AhR, BMAL1, HIF1α, and HIF2α/EPAS1 were clearly hibit marked defects in β cell function, the most characdetectable in mouse islets (data not shown). . This in gene expression could lead to the altered insulin parallels our findings in that the phenotype of the β-ARNT secretion in human type 2 diabetes and that ARNT is a mice was greater in females than in males. Whether the likely upstream regulator of many of these changes. alteration in ARNT in human type 2 diabetes is the re-ARNT is essential for the normal function of HIF1α, sult of exposure to an environmental toxin will require HIF2α, and the aryl hydrocarbon receptor (AhR). These further study. heterodimeric complexes are required for cellular reThe presence of sexual dimorphism is observed in sponses to hypoxia (HIF proteins) and environmental almost all mouse models of diabetes. 
